{"protocolSection":{"identificationModule":{"nctId":"NCT04457479","orgStudyIdInfo":{"id":"HYBRID"},"organization":{"fullName":"Acandis GmbH","class":"INDUSTRY"},"briefTitle":"APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke","officialTitle":"APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-11-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-01-16","type":"ACTUAL"},"completionDateStruct":{"date":"2023-06-30","type":"ACTUAL"},"studyFirstSubmitDate":"2019-12-10","studyFirstSubmitQcDate":"2020-07-02","studyFirstPostDateStruct":{"date":"2020-07-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-08","lastUpdatePostDateStruct":{"date":"2023-08-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Acandis GmbH","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up study to collect comprehensive information on technical and clinical success and safety of the use of APERIO® Hybrid(17/21) Thrombectomy Device in clinical practice. APERIO® Hybrid(17/21) Thrombectomy Device will be used within its approved indication.","detailedDescription":"German APERIO® Hybrid Post- Market Clinical Follow-up Study\n\nAPERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke\n\nStudy Type: prospective, multicenter, single-armed, open-label\n\nParticipants: 8 participating centers in Germany\n\nPI: Dr. Christian Mathys, Evangelisches Krankenhaus Oldenburg, Germany\n\nEstimated Enrolment: 190 patients treated with APERIO® HYBRID(17/21) Thrombectomy Device as a result of an acute stroke\n\nFollow up: 3 months\n\nEstimated Final Assessment: Mid to End of 2023"},"conditionsModule":{"conditions":["Acute Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"3 Months","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":190,"type":"ACTUAL"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Technical success","description":"mTICI ≥ 2b after treatment with APERIO® HYBRID(17/21)","timeFrame":"until 24 hours after intervention"},{"measure":"Good clinical outcome at 90 days","description":"Modified Rankin Scale (mRS) \\< 3 (mRS 1= no symptoms/ good outcome; mRS 6= Patient died/ worse outcome)","timeFrame":"90 days after intervention"},{"measure":"Periprocural symptomatic intracranial hemorrhage (sICH):","description":"ICH in postinterventional (\\<24 hours) CT associated with worsening of NIHSS by ≥ 4 points within 24 hours","timeFrame":"until 24 hours after intervention"}],"secondaryOutcomes":[{"measure":"Cerebrovascular events until hospital discharge:","description":"* Intracranial haemorrhage (symptomatic / asymptomatic)\n* Death\n* TIA in the region of the target vessel\n* Non-disabling ischemic stroke (MRS 0-2) in the region of the target vessel\n* Disabling ischemic stroke (MRS 3-6) in the region of the target vessel\n* TIA outside the region of the target vessel\n* Non-disabling ischemic stroke (MRS 0-2) outside the region of the target vessel\n* Disabling ischemic stroke (MRS 3-6) outside the region of the target vessel","timeFrame":"between 24 hours after intervention and discharge from hospital"},{"measure":"Cerebrovascular events at 90 days","description":"* Intracranial haemorrhage (symptomatic / asymptomatic)\n* Death\n* TIA\n* Non-disabling ischemic stroke (MRS 0-2)\n* Disabling ischemic stroke (MRS 3-6)","timeFrame":"at 90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n- All patients treated with APERIO® HYBRID and/or APERIO® Hybrid(17/21) Thrombectomy Device as a result of an acute stroke.\n\nExclusion Criteria:\n\n* Patient age \\< 18 years\n* Pre stroke mRS ≥ 3","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients diagnosed with acute large vessel occlusion (stroke) treated with the APERIO® Hybrid(17/21) Thrombectomy Device.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Evangelisches Krankenhaus Oldenburg","city":"Oldenburg","zip":"26122","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}